Second-line antiretroviral therapy: long-term outcomes in South Africa. - Wikidata - awgldk - TriplyDB

Second-line antiretroviral therapy: long-term outcomes in South Africa.

Second-line antiretroviral therapy: long-term outcomes in South Africa.

http://www.wikidata.org/entity/Q37158277

about

Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis.Predicting the Need for Third-Line Antiretroviral Therapy by Identifying Patients at High Risk for Failing Second-Line Antiretroviral Therapy in South Africa.Changes in second-line regimen durability and continuity of care in relation to national ART guideline changes in South Africa Virologic outcomes of second-line antiretroviral therapy in Eastern European country of Georgia.Clinical impact and cost-effectiveness of making third-line antiretroviral therapy available in sub-Saharan Africa: a model-based analysis in Côte d'Ivoire.Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens Durability of antiretroviral therapy and predictors of virologic failure among perinatally HIV-infected children in Tanzania: a four-year follow-up.Short term adherence tool predicts failure on second line protease inhibitor-based antiretroviral therapy: an observational cohort study.Association of first-line and second-line antiretroviral therapy adherence.Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria.Projected economic evaluation of the national implementation of a hypothetical HIV vaccination program among adolescents in South Africa, 2012.Marginal Structural Models to Assess Delays in Second-Line HIV Treatment Initiation in South Africa.The combination of pill count and self-reported adherence is a strong predictor of first-line ART failure for adults in South Africa.Pharmacy refill data can be used to predict virologic failure for patients on antiretroviral therapy in Brazil.The Effect of Switching to Second-Line Antiretroviral Therapy on the Risk of Opportunistic Infections Among Patients Infected With Human Immunodeficiency Virus in Northern Tanzania Novel Predictors of Poor Retention Following a Down-Referral from a Hospital-Based Antiretroviral Therapy Program in South Africa.Adherence to Antiretroviral Therapy and Virologic Failure: A Meta-Analysis Can Short-Term Use of Electronic Patient Adherence Monitoring Devices Improve Adherence in Patients Failing Second-Line Antiretroviral Therapy? Evidence from a Pilot Study in Johannesburg, South Africa.Early warning indicators for first-line virologic failure independent of adherence measures in a South African urban clinic.Predictors of treatment failure on second-line antiretroviral therapy among adults in northwest Ethiopia: a multicentre retrospective follow-up study.Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch Treatment outcomes of over 1000 patients on second-line, protease inhibitor-based antiretroviral therapy from four public-sector HIV treatment facilities across Johannesburg, South Africa.Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to lopinavir/ritonavir or nonnucleoside reverse transcriptase inhibitor therapy.Antiretroviral adherence interventions in Southern Africa: implications for using HIV treatments for prevention.Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa.Differences in genetic variants in lopinavir disposition among HIV-infected Bantu Africans.Phenotypic characterization of virological failure following lopinavir/ritonavir monotherapy using full-length Gag-protease genes From research to practice: lay adherence counsellors' fidelity to an evidence-based intervention for promoting adherence to antiretroviral treatment in the Western cape, South Africa.Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor-Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysi Predictors of switch to and early outcomes on third-line antiretroviral therapy at a large public-sector clinic in Johannesburg, South Africa.

P2860

Q33712438-E4C383C0-F615-437A-9E42-BCC1769780C7 Q33733440-BCF2CC7B-F67E-43F3-9E2D-160877E0183E Q33777513-6178AB29-AE57-42D8-93BA-88CE19A970CF Q33914820-70CFF761-6451-4256-AACC-8530B078FE25 Q34097961-809D9FB1-8393-4E7D-9EFC-5E5678EDE55B Q34137798-A5D1BDB1-27E0-4E25-9CFD-5F727E9DB65F Q34475728-ADB2DF4E-6652-472C-8454-F0573C167B2A Q34706948-5B2344CA-EF4A-4843-8391-0633FE115CE1 Q34801978-02BAF9F6-18D9-43F0-8846-603946563169 Q34998736-26BEA9BE-AEA6-43D9-A396-D35BF05CDD91 Q35990326-84BBEC9C-B9FC-4BD6-9FB1-750FA6E4A8CA Q36109276-55F7E443-95BB-467E-8E40-E837D02E25ED Q36168570-D5B23476-63F3-435D-A86B-A6A543599B00 Q36399318-85A521C0-5F54-4B8C-91CD-D1817B5A480F Q36645016-0C35E427-40BA-4A79-932D-97FBF94CF018 Q36756256-69A10E7D-29F9-456E-A65C-1BE476EA7800 Q36822464-8373519C-9925-4667-A14E-C8B2C3F697AD Q37348464-2D7ADC03-BF5F-46E2-9758-F11DAB3C3109 Q37403995-97775361-440D-41E1-B0D2-FBBA3BE376F3 Q37516995-6F1FB558-EBF6-46BB-B0ED-AAE66CEEF77B Q37582314-A7E2CD42-2C19-4B40-AC5E-46ED63E97244 Q37619925-60CAC8A5-92EA-4D52-94CB-BDBFF2EC451A Q37722675-3E5CEADA-01B5-4677-95B7-094A31414948 Q38175876-7A103E2F-58CA-48D8-8210-76A43F327D97 Q38853866-25D3FB06-9854-4F30-8BDF-112A20EE938D Q40688836-0BDA5BF2-2270-4539-A5C7-F44FEF4B97A0 Q42174237-A3787359-6869-491B-B30B-25A576509649 Q43896563-80FACD8C-C503-4947-A0C2-BB6B00433663 Q47258937-6633D511-270E-45BC-818C-76985E634FF9 Q53694036-EDDD5A64-7051-422C-AC11-7AAB15CD6555

P2860

Second-line antiretroviral therapy: long-term outcomes in South Africa.

http://www.wikidata.org/entity/Q37158277

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Second-line antiretroviral therapy: long-term outcomes in South Africa.

@en

Second-line antiretroviral therapy: long-term outcomes in South Africa.

@nl

type

label

Second-line antiretroviral therapy: long-term outcomes in South Africa.

@en

Second-line antiretroviral therapy: long-term outcomes in South Africa.

@nl

prefLabel

Second-line antiretroviral therapy: long-term outcomes in South Africa.

@en

Second-line antiretroviral therapy: long-term outcomes in South Africa.

@nl

P1433

Q37158277-B83209E3-7090-47DE-8B38-BAF0274A8528

P1476

Q37158277-2808BEC2-3622-41D9-9D81-9F364D314249

P2093

Q37158277-14A2BF34-8866-4DBF-B686-64C6F9DD42D9

Q37158277-14C539E7-1D0A-4855-9818-AE8D6B009173

Q37158277-15A13C7E-2BA6-4B4E-8B10-8E36BA419EE5

Q37158277-35B69F3D-C421-46CD-8AA4-34E2534FE83F

Q37158277-50BAD21D-60B5-4E95-9826-D1F303705B71

Q37158277-C47D30A1-907E-423D-ABEE-D75849DDCCC3

Q37158277-FC348335-FCD8-49A7-80DD-93589F6243E0

P2860

Q37158277-015B846B-0E9D-4882-9A68-8BA7721EAE1D

Q37158277-070B6036-1A3A-461D-8E00-1B0FF4A2DB0C

Q37158277-0A5ADEC0-F23E-4CB5-BA75-A67E22F21722

Q37158277-0FCF3418-38A5-4CF8-A9D6-AFE1F1C11224

Q37158277-378D15BE-1397-4108-9071-667EE6659C64

Q37158277-418E0458-A0A2-488A-9873-6F8E765FCB50

Q37158277-4AB622E7-944D-4268-AA0A-87F23AFA044D

Q37158277-53A00D60-2512-4A58-BE54-98900271A11A

Q37158277-54576988-1665-4192-8741-CD17EE18CB66

Q37158277-57F1ACFB-294E-4906-9C9F-9FCFFC1242F1

P304

Q37158277-8D2EE9AD-3E55-4BFD-B48D-32BF8B0DBE14

P31

Q37158277-339D28B2-3101-4659-A787-33EA77BF1579

P356

Q37158277-04080667-5B33-400E-9D0F-718A4C4B6C94

P407

Q37158277-695004AE-C9A4-4241-8020-83F3F6975069

P433

Q37158277-30E86905-E27C-448B-801D-02DC266F0EA2

P478

Q37158277-510000A8-68E6-4042-AD55-E05CF476F7DB

P50

Q37158277-141F2674-FEE9-4781-827A-6C758A6E9408

Q37158277-BBCBC1DD-CA43-470D-85D4-7EF8B41CAE5E

P577

Q37158277-5AC6DB64-F167-4A73-81A9-67FC63BFE12B

P698

Q37158277-F6CBBB70-1126-4D27-975C-1A18A69F2655

P921

Q37158277-22D1B169-1956-4570-A540-1F3E94C39F15

Q37158277-25D5CB29-04D7-4FDD-8F55-2AB9F22563A3

P932

Q37158277-381AA5C2-F13D-4D1E-A568-EAC4CE2B3F98

P356

QAI.0B013E3182615AD1

P1433

Journal of Acquired Immune Deficiency Syndromes

P1476

Second-line antiretroviral therapy: long-term outcomes in South Africa.

@en

P2093

Carmen Castilla

http://www.w3.org/2001/XMLSchema#string

Daniel Kuritzkes

http://www.w3.org/2001/XMLSchema#string

Henry Sunpath

http://www.w3.org/2001/XMLSchema#string

Hoang Nguyen

http://www.w3.org/2001/XMLSchema#string

Jean B Nachega

http://www.w3.org/2001/XMLSchema#string

Richard Court

http://www.w3.org/2001/XMLSchema#string

Shameez Ebrahim

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy

Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa

HIV incidence remains high in KwaZulu-Natal, South Africa: evidence from three districts

Lack of association between retrospectively collected pharmacy refill data and electronic drug monitoring of antiretroviral adherence.

Measuring adherence to antiretroviral treatment in resource-poor settings: the clinical validity of key indicators.

Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa - a prospective cohort study.

The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy.

Outcomes after virologic failure of first-line ART in South Africa

Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa

Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting

P304

158-163

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAI.0B013E3182615AD1

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P50

Vincent C Marconi

P577

2012-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22692090

http://www.w3.org/2001/XMLSchema#string

P921

Aafrikaa Kibbaa

antiretroviral drug

P932

3767995

http://www.w3.org/2001/XMLSchema#string